Trial Profile
A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 (Preladenant) 5 mg BID (P05175)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Preladenant (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
- 20 Feb 2013 New trial record